Restoring metabolic balance AND WEIGHT CONTROL

Harnessing precision-targeted drug formulations for the treatment and prevention of metabolic disorders such as obesity and related diseases

Our Approach

Metabolic disorders such as obesity or type 2 diabetes have emerged as a health and economic problem of global proportions, largely due to excessive consumption of calorie-rich highly refined food, sedentary lifestyles, and disruptions to circadian rhythms in modern work and living environments.

Aphaia is committed to offering patients therapeutic options that provide long-term benefits with minimal or no side effects by restoring the body’s natural physiology.

LEARN MORE

APH-012

LEAD DRUG CANDIDATE

We believe that our drug lead candidate, a proprietary oral glucose formulation, has the potential to revolutionize the treatment of metabolic disorders like obesity, type 2 diabetes, and associated diseases by addressing the underlying disease mechanism. It uniquely activates nutrient-sensing cells in the distal small intestine, restoring the endogenous release of the full spectrum of enteral hormones that control appetite, hunger, satiety, glucose metabolism, and other homeostatic functions.

LEARN MORE

Programs

PHASE 2 TRIALS IN OBESITY AND PREDIABETES

Aphaia’s lead drug candidate is being evaluated in two Phase 2 trials. The first proof-of-concept study in individuals with obesity evaluates its ability to change weight and other key parameters, hallmarking multiple metabolic diseases associated with obesity in a placebo-controlled design. The second trial is evaluating the drug’s ability to help prevent type 2 diabetes.

LEARN MORE

News

Aphaia Pharma Provides Enrollment and Protocol Update for Phase 2 Trial

04/25/2024

Aphaia Pharma Provides Enrollment and Protocol Update for Phase 2 Trial in Individuals with Obesity

Enrollment has been completed for the first two cohorts evaluating a once-daily 12g dose of its oral glucose formulation (APHD-012)
The company is expanding its trial protocol to further explore the contribution of circadian effects in weight loss treatment with four additional cohorts
Topline data anticipated in Q3 and Q4 2024 for cohorts 1-2 and 3-6, respectively

Aphaia Pharma at the 10th LSX World Congress

04/16/2024

Aphaia Pharma to Participate in a Panel Discussion at the 10^th LSX World Congress

ZUG, Switzerland, SAN JUAN, Puerto Rico and TORONTO, April 16, 2024 –
Aphaia Pharma, a clinical-stage company harnessing precision-targeted drug formulations to restore endogenous endocrine balance for the treatment of obesity and associated metabolic diseases, today announced that Steffen-Sebastian Bolz, M.D., Ph.D., Chief Scientific Officer of Aphaia Pharma, will participate in a panel discussion at the 10^th LSX World Congress, taking place April 29-30, 2024 in London, England.

First Patient in Phase 2 Trial Evaluating APH-012 for Prediabetes

04/25/2023

Aphaia Pharma Announces Dosing of First Patient in its Phase 2 Trial Evaluating its Lead Candidate APH-012 for Prediabetes
Aphaia Pharma, a clinical-stage company harnessing precision-targeted drug formulations to restore endogenous endocrine balance for the treatment of obesity and associated metabolic diseases, today announced the first patient has been dosed in a Phase 2 study evaluating the safety and efficacy of its lead candidate, APH-012, to improve glucose tolerance in patients with prediabetes.

All news